CELULARITY INC-A (CELU)
US1511902041 - Common Stock
CELU gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. CELU has a bad profitability rating. Also its financial health evaluation is rather negative. CELU is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CELU had negative earnings in the past year.
In the past year CELU has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CELU reported negative net income in multiple years.
In the past 5 years CELU always reported negative operating cash flow.
1.2 Ratios
CELU's Return On Assets of -107.28% is on the low side compared to the rest of the industry. CELU is outperformed by 78.61% of its industry peers.
Looking at the Return On Equity, with a value of -493.81%, CELU is doing worse than 79.86% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 20.53%, CELU belongs to the top of the industry, outperforming 98.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.28% | ||
| ROE | -493.81% | ||
| ROIC | 20.53% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of CELU (91.18%) is better than 100.00% of its industry peers.
Looking at the Gross Margin, with a value of 53.30%, CELU is in the better half of the industry, outperforming 78.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 91.18% | ||
| PM (TTM) | N/A | ||
| GM | 53.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CELU is creating value.
There is no outstanding debt for CELU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -7.42, we must say that CELU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CELU (-7.42) is worse than 71.84% of its industry peers.
CELU has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
CELU's Debt to Equity ratio of 1.27 is on the low side compared to the rest of the industry. CELU is outperformed by 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.42 |
ROIC/WACC2.04
WACC10.06%
2.3 Liquidity
CELU has a Current Ratio of 0.35. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.35, CELU is not doing good in the industry: 95.90% of the companies in the same industry are doing better.
A Quick Ratio of 0.29 indicates that CELU may have some problems paying its short term obligations.
CELU has a worse Quick ratio (0.29) than 95.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.35 | ||
| Quick Ratio | 0.29 |
3. Growth
3.1 Past
CELU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1322.50%.
The Revenue has grown by 109.81% in the past year. This is a very strong growth!
EPS 1Y (TTM)-1322.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.08%
Revenue 1Y (TTM)109.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%273.09%
3.2 Future
CELU is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.54% yearly.
The Revenue is expected to grow by 48.52% on average over the next years. This is a very strong growth
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CELU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CELU's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CELU is cheaper than 99.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.92 |
4.3 Compensation for Growth
A cheap valuation may be justified as CELU's earnings are expected to decrease with -9.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CELU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CELULARITY INC-A
NASDAQ:CELU (11/11/2024, 8:26:02 PM)
Premarket: 3.32 -0.1 (-2.92%)3.42
-0.13 (-3.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap75.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.28% | ||
| ROE | -493.81% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 91.18% | ||
| PM (TTM) | N/A | ||
| GM | 53.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.35 | ||
| Quick Ratio | 0.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1322.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-62.86%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)109.81%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y